… COX-2 inhibitors with CRT to treat patients with cervical cancer, our results and those from
the RTOG trial suggest that the potential toxicity of COX-2 inhibitors probably offsets any small …

… To evaluate the toxicity and biomarker response of celecoxib (C) as a biologic modifier in …
) in women with cervix cancer. Fifteen cervix patients were entered into the first phase of this …

… of cyclooxygenase-2 (COX-2) in the development of cervical … for two clinical trials of
celecoxib in advanced cervical cancer. … Phase I/II study of selective cyclooxygenase-2 inhibitor …

… In a phase I–II trial of celecoxib 400 mg twice per day for 2 … , 31 patients with locally advanced
cervical cancer were enrolled. … Clinical trials of cyclooxygenase-2 (COX-2) inhibitors for the …

… in immune cells in the tumour microenvironment, leading to loss of … In a cervical cancer
cell line, celecoxib increased … in normal and cancer cells; although these biomarkers and cell …

… phase I/II studies (1, 2) of cervical cancer treated with chemoradiotherapy (CRT) and celecoxib
… in the recent trial using celecoxib (1) compared with their historical data of CRT (6.9%) for …

… factor receptor, cell cycle, histone deacetylases, cyclooxygenase-2 (COX-2), or … celecoxib
retrieved (109 patients) [29], [30], [31], both of them described the results of phase I/II trials…

… and tumor size; (4.1) the assay used to measure biomarker expression … Cyclooxygenase-2
is an important enzyme in the conversion of … However, celecoxib in combination with standard …

156 A prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with
carcinoma of the cervix with biomarker assessment of the tumor micro environment … People …

224 A prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with
carcinoma of the cervix with biomarker assessment of the tumour micro environment … People …